San Diego Life Sciences Roundup: BeneChill, Sotera, Imthera, & More

12/16/11Follow @bvbigelow

—After naming former Boston Scientific executive Fred Colen as CEO last month, San Diego’s BeneChill raised nearly $15 million in a round that’s targeting a total of $25.6 million, according to a recent regulatory filing. BeneChill, founded in 2004, has been developing therapeutic hypothermia medical products. The company’s European headquarters is in Lausanne, Switzerland, and BeneChill has European approval to sell its intra-nasal cooling system—which induces therapeutic hypothermia immediately following cardiac arrest.

—San Diego’s Sotera Wireless has been busy getting its ducks in a row. After applying for FDA approval of its vital signs wireless patient care monitoring technology in August, Sotera raised $12.2 million last week in Series D financing. Sotera said it also signed a commercial partnership agreement with Kansas City, MO-based Cerner, the giant health IT systems provider. If all goes as planned, funding from the current financing round will be used to support the launch of Sotera’s “ViSi Mobile System” in early 2012.

—Melinda Richter, the founder and CEO of San Francisco-based Prescience International sat down with me to discuss her plans for the life sciences incubator going in at Johnson & Johnson’s pharmaceutical R&D facility in San Diego. The J&J facility, known as the Janssen Labs at San Diego, will host 18 to 20 early stage startups. Richter, who will manage the facility under a contract with Janssen, said she wants to dramatically lower the costs for starting a life sciences company.

Optimer Pharmaceuticals (NASDAQ: OPTR) said it won approval to start selling its new antibiotic, fidaxomicin (Dificlir) in Europe as a new treatment for C. difficile infections of the gut. Japan’s Astellas Pharmaceuticals has the rights to … Next Page »

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.